Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - TENAX THERAPEUTICS, INC. | Financial_Report.xls |
| 10-Q - QUARTERLY REPORT - TENAX THERAPEUTICS, INC. | oxbt_10q.htm |
| EX-3.1 - AMENDED AND RESTATED BYLAWS - TENAX THERAPEUTICS, INC. | oxbt_ex31.htm |
| EX-10.9 - RESTRICTED STOCK AWARD AGREEMENT - TENAX THERAPEUTICS, INC. | oxbt_ex109.htm |
| EX-31.1 - CERTIFICATION - TENAX THERAPEUTICS, INC. | oxbt_ex311.htm |
EXHIBIT 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Oxygen Biotherapeutics, Inc. (the “Company”) on Form 10-Q for the period ended October 31, 2011 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael B. Jebsen, Interim Chief Executive Officer, Secretary and Chief Financial Officer (Principal Executive Officer) of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Date: December 15, 2011
|
|
/s/ Michael B. Jebsen | |
| Michael B. Jebsen, | |||
| Interim Chief Executive Officer, President and Chief Financial Officer | |||
| (Principal Executive Officer) |
The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing